Ruxience (Rituximab)
What is a Generic Drug?
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Coming Soon – Save up to 85%
Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.
Prescription Required
-
Product Details
Description
Ruxience (rituximab-pvvr) is a medication that is given via an intravenous (IV) infusion to treat adults with non-Hodgkin's Lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, or granulomatosis with polyangiitis and microscopic polyangiitis.
Fact Table
Formula
C6416H9874N1688O1987S44
License
US FDA, EMA
Bioavailability
Not applicable (IV administration)
Legal status
Prescription only (Rx)
Chemical Name
Rituximab
Elimination half-life
18 days
Dosage (Strength)
100 mg/10 mL, 500 mg/50 mL
Pregnancy
Consult a doctor
Brands
Ruxience, Rituxan, MabThera, Truxima
Protein binding
Not reported
PubChem CID
50943701
MedlinePlus
a607038
ChEBI
CHEBI:134722
ATC code
L01XC02
DrugBank
DB00073
KEGG
D02995
Routes of administration
Intravenous (IV)
Directions
Your doctor will determine an appropriate treatment regimen for you. Ruxience will be administered via an IV infusion by a healthcare professional. Inform your doctor of any questions or concerns you may have about the medication.
Ingredients
The active ingredient in Ruxience is rituximab-pvvr.
Inactive ingredients include edetate disodium dihydrate, L-histidine, L-histidine hydrochloride monohydrate, polysorbate 80, sucrose, and Water for Injection.
Contraindications
There are no contraindications to Ruxience per the most recent Prescribing Information.
Cautions
- Ruxience contains the following FDA Boxed Warning:
- Infusion-related reactions that can be fatal may occur within 24 hours of rituximab infusion; approximately 80% of fatal reactions occurred with first infusion. Patients should be monitored, and Ruxience should be stopped if severe reactions occur.
- Severe mucocutaneous reactions can occur, which may be fatal.
- Reactivation of hepatitis B virus (HBV) that may result in fulminant liver inflammation, liver failure, and death can occur.
- Progressive multifocal leukoencephalopathy (PML) may occur and can result in death.
- Before you begin treatment with Ruxience, inform your doctor of:
- All the prescription and over-the-counter medications you take
- Your allergies
- Your current health problems and past medical history
- Your pregnancy or breastfeeding status
- Ruxience is associated with the following warnings and precautions:
- Tumor lysis syndrome
- Infections
- Cardiac adverse reactions
- Kidney problems
- Bowel obstruction and perforation
- Harm to an unborn baby. Effective contraception is recommended for females of childbearing age during treatment with Ruxience and for 12 months after the final dose.
- Breastfeeding is not recommended.
- Live vaccines should not be administered to patients receiving Ruxience.
Side Effects
Infusion-related reactions, fever, decreased lymphocytes, chills, infection, weakness, upper respiratory tract infections, nasopharyngitis, urinary tract infections, bronchitis, nausea, diarrhea, headache, muscle spasms, anemia, and swelling are common Ruxience side effects; however, other side effects may also occur. Immediately inform your doctor of any side effects that bother you or won’t go away.
Ask your doctor about Ruxience.
Reference
Ruxience. New York, NY: Pfizer Labs; 2023.
IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.Product Code : 14560
-
Product Reviews
